Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R4X" target="_blank" >RIV/61988987:17110/17:A1801R4X - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/17:00067547 RIV/00843989:_____/17:E0106411 RIV/61989592:15110/17:73581190
Result on the web
<a href="http://dx.doi.org/10.1080/10428194.2017.1298755" target="_blank" >http://dx.doi.org/10.1080/10428194.2017.1298755</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2017.1298755" target="_blank" >10.1080/10428194.2017.1298755</a>
Alternative languages
Result language
angličtina
Original language name
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Original language description
Introduction: Carfilzomib is a selective proteasome inhibitor that is approved in the United States and other countries for the treatment of relapsed and refractory multiple myeloma. The randomized, open-label, multicenter, phase 3 study ENDEAVOR (NCT01568866) met its primary end point, demonstrating a statistically and clinically significant improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) compared with bortezomib and dexamethasone (Vd) (median 18.7 vs 9.4 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.44-0.65; 1-sided P <0.001) (Dimopoulos et al, J Clin Oncol 2015;33:abstr 8509; Dimopoulos et al, Haematologica 2015;100[s1]:abstr LB2071). Herein we present results of a preplanned subgroup analysis of efficacy and safety outcomes of the ENDEAVOR study according to age.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
LEUKEMIA & LYMPHOMA
ISSN
1042-8194
e-ISSN
1029-2403
Volume of the periodical
58
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
2501-2504
UT code for WoS article
000404572000031
EID of the result in the Scopus database
2-s2.0-85015635745